Clinical trials: Asymptomatic HIV
HIV Infections
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC.
- Trial name
- NCT00000736
- Testing
- Zidovudine
- Where
- 43 sites in United States
- Volunteers
- 3,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given subcutaneously in conjunction with antiviral treatment and to explore the effects of treatment on surrogate markers of efficacy and incidence of…
- Trial name
- NCT00001997
- Testing
- Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
- Where
- United States
- Sponsor
- Chiron Corporation
HIV
Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
The proposed research will include adolescent and young adult Hispanic/Latino men who have sex with men (MSM) and heterosexual men and women, aged 13-24 years, and will be based at 13 ATN Adolescent Medicine Trial Units (AMTUs)…
- Trial name
- NCT01203332
- Testing
- Effectiveness of different strategies in HIV testing and linkage to care
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 1,917 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
This protocol represents the first in human study of TUTI-16, and is being conducted to establish the safety and human immunogenicity (anti-HIV-1 Tat titers) of subcutaneously administered TUTI-16.
- Trial name
- THYMON-08001 (NCT00848211)
- Testing
- TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thymon, LLC
HIV Infections
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
To determine the safety and immunogenicity of gp160 (MicroGeneSys), rgp120/HIV-1MN (Genentech), and rgp120/HIV-1SF2 (BIOCINE) and their adjuvants in HIV-infected children 1 month to 18 years of age.
- Trial name
- NCT00000762
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients
To determine the safety and effectiveness of treatment with ribavirin (RBV) plus isoprinosine (INPX) in preventing the development of AIDS in patients infected with the AIDS virus (HIV).
- Trial name
- NCT00000699
- Testing
- Inosine pranobex, Ribavirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
AMENDED: To investigate whether subcutaneous (SC) injection of IL-2 produces biological responses which parallel those observed with IV dosing.
- Trial name
- NCT00001005
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
To determine the minimal effective (immunogenic) dose of vaccine in asymptomatic HIV-1 seropositive individuals with > 400 cells/mm3 (CD4). To determine the dose-response to a 4 fold escalation of the immunizing dose.
- Trial name
- NCT00000977
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment.
- Trial name
- NCT00002324
- Testing
- Nevirapine, Zidovudine
- Where
- 18 sites in United States
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study of Anti-HIV Monoclonal Antibody KD-247
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and…
- Trial name
- NCT00917813
- Testing
- KD-247, Physiological saline
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
Asymptomatic HIV, HIV Infections
ID and Testing Via Friendship Networks
This is a pilot study with a cross-sectional research design to recruit Hispanic/Latina and African American adolescent and young adult women, aged 13-24 years to serve as index recruiters, who will in turn recruit members of her…
- Trial name
- NCT00841360
- Testing
- Index Recruiter, Friendship Network Member
- Where
- 3 sites in United States
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Leishmaniasis, Visceral
Predicting Visceral Leishmaniasis in HIV Infected Patients
In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an…
- Trial name
- PreLeisH (NCT03013673)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 566 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Asymptomatic Leishmania Infection in HIV Patients
To collect pilot data on the prevalence and incidence of asymptomatic Leishmania donovani infection in HIV infected individuals in a visceral leishmaniasis (VL)-HIV endemic region to inform the feasibility of a larger study…
- Trial name
- NCT02839603
- Where
- Ethiopia
- Volunteers
- 540 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered in combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3.
- Trial name
- NCT00002079
- Testing
- Butyldeoxynojirimycin, Zidovudine
- Where
- 9 sites in United States
- Sponsor
- G D Searle
Asymptomatic HIV Infection
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
This study will evaluate the safety, tolerability, antiretroviral activity, pharmacokinetics, and pharmacodynamics of an intravenous formulation of deferiprone in HIV-infected subjects.
- Trial name
- NCT02456558
- Testing
- Intravenous deferiprone
- Where
- 2 sites in South Africa
- Volunteers
- 30 people
- Sponsor
- ApoPharma
HIV Infections
Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease
To validate that the alteration of codon 215 of reverse transcriptase in plasma virus precedes the increase in viral burden as measured in the peripheral blood and the decline in CD4 count that have been observed in association…
- Trial name
- NCT00001045
- Testing
- Nevirapine, Zidovudine, Didanosine
- Where
- 59 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
To evaluate the safety of anti-HIV CTL therapy in early stage patients and to verify the safety when combined with antiviral therapy with zidovudine/lamivudine/indinavir and low-dose interleukin-2 (IL-2).
- Trial name
- NCT00000875
- Testing
- Indinavir sulfate, Diphenhydramine hydrochloride, Lymphocytes, Activated
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects
To characterize the pharmacokinetics of orally administered FLT (in a liquid formulation) after single doses in both the fed and fasting states; to assess the effect of food on the oral bioavailability of FLT
- Trial name
- NCT00002260
- Testing
- Alovudine
- Where
- United States
- Sponsor
- Lederle Laboratories
Virus-HIV
Coronary Artery Disease (CAD) in Suppressed HIV-infected
HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD.
- Trial name
- NCT02898896
- Testing
- blood test
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding.
- Trial name
- NCT00002373
- Testing
- Maribavir
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Glaxo Wellcome